We are live on ! Find out more

Dentsply Sirona

XRAY

Market cap $1.9B

9.54 USD

+0.16

1.71%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

9.55

+0.01

0.1%

1 day

1.71%

5 days

-8.88%

1 month

-14.13%

3 months

-7.65%

6 months

-17.69%

Year to date

-15.35%

1 year

-28.91%

5 years

-84.01%

10 years

-84.03%

About: Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantology. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers.

Employees: 14,000

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 22.2%

Neutral 61.1%

Negative 16.7%

Zacks Investment Research

Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for Now

XRAY's digital dentistry, R&D and restructuring support growth, but CAD/CAM, implants, SureSmile and tariff pressures pose near-term risks.

Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for Now

Zacks Investment Research

XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure

XRAY beat Q2 earnings and revenue estimates, held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery.

XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure

Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Dentsply Sirona to Participate in the Baird 2026 Global Healthcare Conference

CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Baird 2026 Global Healthcare Conference. Management is scheduled to present on Tuesday, September 15, 2026, at 11:25 a.m. ET.

Dentsply Sirona to Participate in the Baird 2026 Global Healthcare Conference

Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities

"I'll give you 950 billion reasons to buy bonds right now," says Thomas Hayes, who gives a contrarian take on why investors should bolster their portfolios in fixed income. He discusses the "seasonality effect," a crowded AI trade, a complicated geopolitical picture, and a steady rise in crude oil as components he sees leading a lasting bond rally.

Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities

New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence

New system completes the Surity™ portfolio of external catheters for both men and women Integrates into daily routines to help support management of urinary incontinence at home Designed to operate quietly overnight, new Surity™ System helps minimize nighttime interruptions to support comfort and rest MÖLNDAL, Sweden, Aug. 19, 2026 /PRNewswire/ -- Wellspect HealthCare today announced the U.S. launch of the Surity™ Urinary Management System, a discreet at-home urine collection device designed to support people living with urinary incontinence and those who help care for them. This completes the full Surity™ portfolio in the U.S., following the introduction of the Surity™ Female and Male External Catheters earlier this year.

New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence

DENTSPLY SIRONA Q2 Earnings Call Highlights

DENTSPLY SIRONA NASDAQ: XRAY reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis, as the dental products company continued its turnaround plan amid lower volumes in several businesses and distributor inventory reductions in Europe.

DENTSPLY SIRONA Q2 Earnings Call Highlights

Zacks Investment Research

XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.

XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

Zacks Investment Research

Here's What Key Metrics Tell Us About Dentsply (XRAY) Q2 Earnings

The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Dentsply (XRAY) Q2 Earnings

DENTSPLY SIRONA Inc. (XRAY) Q2 2026 Earnings Call Transcript

DENTSPLY SIRONA Inc. (XRAY) Q2 2026 Earnings Call Transcript

DENTSPLY SIRONA Inc. (XRAY) Q2 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™